Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
Status:
Completed
Trial end date:
2020-08-25
Target enrollment:
Participant gender:
Summary
The investigators are imaging patients with prostate cancer using a new Positron Emission
Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect
prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Thomas Hope University of California, San Francisco